𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Progression of Cutaneous B-Cell Pseudolymphoma to Cutaneous B-Cell Lymphoma

✍ Scribed by Brittain F. Kulow; Hernani Cualing; Paul Steele; Judi VanHorn; John C. Breneman; Diya F. Mutasim; Debra L. Breneman


Publisher
Springer-Verlag
Year
2002
Tongue
English
Weight
320 KB
Volume
6
Category
Article
ISSN
1203-4754

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Dual genotype in cutaneous T-cell lympho
✍ Y. J. Bignon; P. Souteyrand; H. Roger; D. Bernard; B. Dastugue; F. Ramos; M. d'I πŸ“‚ Article πŸ“… 1990 πŸ› Springer 🌐 English βš– 397 KB

Genomic DNA digests of skin biopsies from 20 patients with cutaneous T-cell lymphomas and pseudolymphomas were studied by hybridization, using probes for the constant region of the T-cell receptor beta chain and the joining region of the immunoglobin heavy chain gene. Skin biopsies from all 20 patie

Specific immune therapy-related cutaneou
✍ G Gerlini; M Mori; D Massi; N Pimpinelli πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 478 KB

## ABSTRACT We report two cases of cutaneous B‐cell pseudolymphoma (PCBCL) induced by intradermal antigen injections for specific immune therapy (SIT). In both cases, the lesions had first developed on the area of injection; years later, new lesions appeared far from the original site. The histolog

Detection of Epstein-Barr virus genome i
✍ K. Peris; H. Niedermeyer; L. Cerroni; T. Radaskiewicz; S. Chimenti; H. HΓΆfler πŸ“‚ Article πŸ“… 1994 πŸ› Springer-Verlag 🌐 English βš– 772 KB

The Epstein-Barr virus (EBV) genome has recently been identified in Hodgkin's disease (HD) and nodal non-Hodgkin's lymphomas (NHL). In order to elucidate the possible aetiopathogenetic role of EBV in benign and malignant lymphoproliferative disorders we investigated skin specimens from 24 patients w

Rituximab in cutaneous B-cell lymphoma:
✍ R.A. Sabroe; F.J. Child; A.J. Woolford; M.F. Spittle; R. Russell-Jones πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 416 KB

We report two patients with primary cutaneous B-cell lymphoma who were treated with rituximab, a new anti-CD20 monoclonal antibody. The first patient, who had a diffuse large B-cell lymphoma of the lower leg, achieved an 85% improvement. The second patient, who had a primary cutaneous B-cell lymphom